MSB 2.50% $1.46 mesoblast limited

Ann: FDA Agrees to Rolling Review of Mesoblast BLA Submission, page-2

  1. 5,779 Posts.
    lightbulb Created with Sketch. 591
    Well we now know they have had the meeting, but as for the rest IMO we already knew all of this ?  

    New York, USA; and Melbourne, Australia, April 16, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has agreed that Mesoblast can submit on a rolling basis a Biologics License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease (SR-aGVHD).

    Mesoblast will submit each module of the BLA to the FDA on a rolling basis as it is completed. The rolling process will provide opportunity for ongoing and frequent communication, and during this process the Company expects it will be able to adequately address any substantial matters raised by the FDA.

    Mesoblast has previously received Fast Track designation from the FDA for remestemcel-L in SRaGVHD and is eligible for priority review once the BLA filing is completed and accepted by the FDA. Mesoblast expects to submit the first module shortly.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $747.9M
Open High Low Value Volume
$1.48 $1.49 $1.46 $333.3K 226.7K

Buyers (Bids)

No. Vol. Price($)
2 1317 $1.46

Sellers (Offers)

Price($) Vol. No.
$1.47 383 2
View Market Depth
Last update - 11.17am 24/05/2019 (20 minute delay) ?
-0.038 ( 2.71 %)
Open High Low Volume
$1.48 $1.48 $1.46 28167
Last updated 11.26am 24/05/2019 (live) ?
MSB (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.